论文部分内容阅读
血管紧张素转化酶(Angiotensin Con-verting Enzyme,ACE)抑制剂是一类新型的心血管药物。自1980年Squibb公司的巯甲丙脯酸(Captopril),1984年Merck公司的苯酯丙脯酸(Enalapril)相继上市以来,近年来又发现了许多具有较强酶抑制活性的化合物。其中2个新药已上市,3个正待注册,约10个化合物已进入三期临床阶段,另外还有20～30个化合物正在进一步研究。上市新药目前市场上除了巯甲丙脯酸和苯酯丙脯酸的单一制剂外,还有其和利尿剂氯噻嗪(HCTZ)的联合制剂(商品名分别为(Cap-ozide和Vaserfic)。联合用药比ACE抑制剂
Angiotensin-converting enzyme (ACE) inhibitor is a new class of cardiovascular drugs. Since Captopril of Squibb Company in 1980 and Enalapril of Merck Company in 1984 came into the market one after another, many compounds having stronger enzyme inhibitory activity have been discovered in recent years. Two of the new drugs are on the market, three are pending registration, about 10 have entered the phase III clinical phase, and another 20 to 30 are in the pipeline. New drugs marketed In addition to single agents such as captopril and phenylpropionate, there is a combination formulation with hydrochlorothiazide (HCTZ) (Cap-ozide and Vaserfic, respectively). Combination therapy than ACE inhibitors